Therapeutically active compounds and their methods of use
Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.
1. A pharmaceutical composition comprising a crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol mesylate and at least one pharmaceutically acceptable carrier or adjuvant, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 40 .
2. The pharmaceutical composition of claim 1 for oral administration.
3. The pharmaceutical composition of claim 2 , wherein the composition is a tablet.
4. A pharmaceutical composition comprising a crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol mesylate and at least one pharmaceutically acceptable carrier or adjuvant, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 43 .
5. The pharmaceutical composition of claim 4 for oral administration.
6. The pharmaceutical composition of claim 5 , wherein the composition is a tablet.
7. A method of treating an advanced hematologic malignancy in a subject, wherein the advanced hematologic malignancy is selected from acute myelogenous leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2, comprising administering to the subject the pharmaceutical composition of claim 1 .
8. The method of claim 7 , wherein the advanced hematologic malignancy is acute myelogenous leukemia.
9. The method of claim 8 , wherein the acute myelogenous leukemia is relapsed or primary refractory.
10. A method of treating an advanced hematologic malignancy in a subject, wherein the advanced hematologic malignancy is selected from acute myelogenous leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2, comprising administering to the subject the pharmaceutical composition of claim 4 .
11. The method of claim 10 , wherein the advanced hematologic malignancy is acute myelogenous leukemia.
12. The method of claim 11 , wherein the acute myelogenous leukemia is relapsed or primary refractory.